Keeping you up to date on recent developments in oncology, including: Cancer mortality rates falling, but incidence rising among women; Camouflage for better nano-treatments for cervical cancer; Deep learning may boost glial segmentation studies.
Keeping you up to date on recent developments in oncology, including: Cost effectiveness of biomarker testing for lung cancer screening eligibility still iffy; Unexpected mechanism, combination possibilities for CDK 4/6 inhibitors; Protons pushing into Peoria; BWXT on the move in Tc-99 production.
Keeping you up to date on recent developments in diagnostics, including: Question of COVID-19 contagion window; A paper-based, portable coronavirus test; Finding the next pandemic threat early on; Anatomy study reveals schizophrenia subtypes.
Keeping you up to date on recent developments in oncology, including: Study identifies two different cancer stem cells in cervical cancer; How cancer cells hibernate…; …And who makes their bed; Blocking trash trashes MSI-hi tumors.
New York and Rehovot, Israel-based in vitro diagnostics startup Todos Medical Ltd. is developing blood tests for the early detection of cancer and neurodegenerative diseases using Fourier-transform infrared (FTIR) spectroscopy. Now the company is looking to apply the technology in diagnosing infections, including the novel coronavirus, COVID-19.
Keeping you up to date on recent developments in oncology, including: Study demonstrates time travel possible for pancreatic cancer; Angle’s Parsotix fares well in new study; New technique boosts utility of organoids; Smart microwaves take on breast cancer.
Keeping you up to date on recent developments in oncology, including: New approach to photothermal treatment beats biofilm problem; Origin story helps ovarian cancer prognosis; Sharper look yields new potential kinase target in ovarian cancer; Autophagy activation may prevent metastasis.
Two of three oncology drugs selected for blockbuster status in the Cortellis Drugs to Watch analysis are antibody-drug conjugates (ADCs), highly targeted cancer therapies designed to leave the healthy cells be and zap the bad ones. What once was a dead end for development has morphed into a competitive space with 57 ADC candidates for cancer indications in phase I or later trials, according to Cortellis.
No matter how effective it is, a drug is worthless if the people who need it can’t afford it. That’s been almost an anthem for patients and policy wonks testifying before U.S. Congress on drug prices.
New analysis from Clarivate Analytics' Cortellis Forecast Team predicts 11 medicines set to enter the market in 2020 will reach more than $1 billion in sales by 2024.
RSS
